All In Biotech

Drug Trial Radar · NCT06590857

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) in Subjects With Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) (TRACY-1).

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Jul 19, 2024

Primary completion

Oct 2028

Study completion Nov 2033

Sponsor

Lead sponsor
RayzeBio, Inc.Industry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

Conditions

  • Metastatic Breast Cancer
  • HER2-negative Breast Cancer
  • ER+ Breast Cancer
  • Advanced Breast Cancer
  • Metastatic Breast Cancer With Bone Involvement
  • Bone Metastases in Subjects With Advanced Breast Cancer
  • ER-Positive HER2-Negative Breast Cancer
  • Estrogen Receptor-positive Breast Cancer
  • Hormone-sensitive Metastatic Breast Cancer
  • Hormone-Sensitive Breast Cancer

Interventions

  • RYZ101Drug

    Ac-225

  • Standard of Care Endocrine TherapyDrug

    Investigator's choice of endocrine therapy, such as, anastrozole, elacestrant, exemestane, fulvestrant, imlunestrant, letrozole, tamoxifen, or vepdegestrant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose EscalationTime frame: 6 weeks of RYZ101 treatment
  2. Endocrine Therapy Combination Dose EscalationTime frame: [Time Frame: 6 weeks of study treatment]
  3. Endocrine Therapy Combination Dose EscalationTime frame: Up to approximately 5 years after the last subject has completed RYZ101 treatment
  4. Endocrine Therapy Combination Dose Escalation and ExpansionTime frame: Up to approximately 5 years after the last subject has completed RYZ101 treatment
  5. Endocrine Therapy Combination Dose Escalation and ExpansionTime frame: Up to approximately 5 years after the last subject has completed RYZ101 treatment

Locations

32 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Facility

    Phoenix, Arizona · Not yet recruiting

  • Research Facility

    Irvine, California · Not yet recruiting

  • Research Facility

    San Diego, California · Not yet recruiting

  • Research Facility

    Santa Monica, California · Recruiting

  • Research Facility

    Longmont, Colorado · Recruiting

  • Research Facility

    Jacksonville, Florida · Not yet recruiting

  • Research Facility

    Atlanta, Georgia · Not yet recruiting

  • Research Facility

    Indianapolis, Indiana · Recruiting

  • Research Facility

    Boston, Massachusetts · Not yet recruiting

  • Research Facility

    Detroit, Michigan · Not yet recruiting

  • Research Facility

    Maplewood, Minnesota · Not yet recruiting

  • Research Facility

    Rochester, Minnesota · Not yet recruiting

  • Research Facility

    St Louis, Missouri · Not yet recruiting

  • Research Facility

    Omaha, Nebraska · Recruiting

  • Research Facility

    Albuquerque, New Mexico · Not yet recruiting

  • Research Facility

    Buffalo, New York · Not yet recruiting

  • Research Facility

    New York, New York · Not yet recruiting

  • Research Facility

    New York, New York · Not yet recruiting

  • Research Facility

    Cleveland, Ohio · Not yet recruiting

  • Research Facility

    Philadelphia, Pennsylvania · Not yet recruiting

  • Research Facility

    Pittsburgh, Pennsylvania · Not yet recruiting

  • Research Facility

    Dallas, Texas · Not yet recruiting

  • Research Facility

    Houston, Texas · Not yet recruiting

  • Research Facility

    Salt Lake City, Utah · Not yet recruiting

  • Research Facility

    Norfolk, Virginia · Not yet recruiting

  • Research Facility

    Seattle, Washington · Recruiting

  • Research Facility

    Vancouver, British Columbia, Canada · Recruiting

  • Research Facility

    Toronto, Ontario, Canada · Not yet recruiting

  • Research Facility

    Toronto, Ontario, Canada · Not yet recruiting

  • Research Facility

    Québec, Quebec, Canada · Not yet recruiting

  • Research Facility

    Seoul, Seoul, South Korea · Active not recruiting

  • Research Facility

    Seoul, Seoul, South Korea · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.